BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 29313360)

  • 1. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
    Dyrberg E; Larsen EL; Hendel HW; Thomsen HS
    Acta Radiol; 2018 Sep; 59(9):1119-1125. PubMed ID: 29313360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective Study Comparing
    Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
    J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
    Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Dyrberg E; Hendel HW; Huynh THV; Klausen TW; Løgager VB; Madsen C; Pedersen EM; Pedersen M; Thomsen HS
    Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.
    Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O
    Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
    Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
    BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
    Zhou J; Gou Z; Wu R; Yuan Y; Yu G; Zhao Y
    Skeletal Radiol; 2019 Dec; 48(12):1915-1924. PubMed ID: 31127357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective comparative study of
    Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
    Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
    World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
    Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
    AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Sheikhbahaei S; Jones KM; Werner RA; Salas-Fragomeni RA; Marcus CV; Higuchi T; Rowe SP; Solnes LB; Javadi MS
    Ann Nucl Med; 2019 May; 33(5):351-361. PubMed ID: 30877561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?
    de Leiris N; Leenhardt J; Boussat B; Montemagno C; Seiller A; Phan Sy O; Roux J; Laramas M; Verry C; Iriart C; Fiard G; Long JA; Descotes JL; Vuillez JP; Riou L; Djaileb L
    Cancer Imaging; 2020 Aug; 20(1):58. PubMed ID: 32787923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
    Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
    Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for Modernising Imaging in Advanced Prostate Cancer.
    Padhani AR; Lecouvet FE; Tunariu N; Koh DM; De Keyzer F; Collins DJ; Sala E; Fanti S; Vargas HA; Petralia G; Schlemmer HP; Tombal B; de Bono J
    Eur Urol Focus; 2017 Apr; 3(2-3):223-239. PubMed ID: 28753774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-individual comparison of
    Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
    Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
    Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
    Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Langsteger W; Rezaee A; Pirich C; Beheshti M
    Semin Nucl Med; 2016 Nov; 46(6):491-501. PubMed ID: 27825429
    [No Abstract]   [Full Text] [Related]  

  • 19. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer].
    Garcia JR; Moreno C; Valls E; Cozar P; Bassa P; Soler M; Alvarez-Moro FJ; Moragas M; Riera E
    Rev Esp Med Nucl Imagen Mol; 2015; 34(3):155-61. PubMed ID: 25443648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
    Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
    Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.